Skip to main content

Table 1 Prognostic power of the TSTSS in three independent ER+ breast cancer datasets

From: An integrated genomic approach identifies persistent tumor suppressive effects of transforming growth factor-β in human breast cancer

  

Breast cancer cohort

  

GSE6532 (Loi)

NKI

TCGA

Variable

Ref for HR = 1

Hazard ratio

CI

Pvalue

Hazard ratio

CI

Pvalue

Hazard ratio

CI

Pvalue

TSTSS

High

1.89

1.1-3.27

0.02211

1.81

1.12-2.93

0.01535

2.6

1.21-5.58

0.0142

metaPCNA

Low

2.32

1.27-4.24

0.006251

1.67

0.96-2.92

0.07143

0.77

0.38-1.58

0.4788

Age

Low*

1.03

0.63-1.69

0.9

0.52

0.32-0.84

0.007841

1.88

0.94-3.75

0.07393

Node

Negative

0.91

0.54-1.53

0.7113

0.84

0.52-1.34

0.4651

2.33

1.07-5.08

0.03389

Grade

Grade 1

0.99

0.67-1.47

0.9798

1.57

1.1-2.25

0.01365

na

na

na

Size

Continuous

1.33

1.09-1.62

0.005177

1.22

0.95-1.57

0.1109

na

na

na

  1. Multivariate analysis was performed using the Cox proportional hazards model. Nineteen out of the 26 genes of the TSTSS were found in the GSE6532 (Loi) and NKI cohorts, and 24 out of 26 genes were found in the TCGA cohort. The TSTSS was analyzed as a binary variable where high indicates higher than median expression. The hazard ratio refers to distant metastasis-free survival for GSE6532 and NKI, and overall survival for TCGA. The metaPCNA index is a surrogate for proliferation and low indicates lower than median expression. Parameters for the TSTSS are highlighted in bold. *Low is ≤61 yrs (GSE6532); ≤45 yrs (NKI); ≤60 yrs (TCGA). HR, hazard ratio; CI, confidence interval; TSTSS, TGF-β/Smad3 tumor suppressor signature; na, not available.